1. COVID-19 Is a Coronary Artery Disease Risk Equivalent and Exhibits a Genetic Interaction With ABO Blood Type.
- Author
-
Hilser, James R, Spencer, Neal J, Afshari, Kimia, Gilliland, Frank D, Hu, Howard, Deb, Arjun, Lusis, Aldons J, Wilson Tang, WH, Hartiala, Jaana A, Hazen, Stanley L, and Allayee, Hooman
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Clinical Sciences ,Coronaviruses ,Atherosclerosis ,Emerging Infectious Diseases ,Cardiovascular ,Heart Disease ,Infectious Diseases ,Heart Disease - Coronary Heart Disease ,Genetics ,2.1 Biological and endogenous factors ,Good Health and Well Being ,COVID-19 ,SARS-CoV-2 ,genetics ,major adverse cardiac events ,myocardial infarction ,stroke ,thrombosis ,Cardiorespiratory Medicine and Haematology ,Cardiovascular System & Hematology ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
BackgroundCOVID-19 is associated with acute risk of major adverse cardiac events (MACE), including myocardial infarction, stroke, and mortality (all-cause). However, the duration and underlying determinants of heightened risk of cardiovascular disease and MACE post-COVID-19 are not known.MethodsData from the UK Biobank was used to identify COVID-19 cases (n=10 005) who were positive for polymerase chain reaction (PCR+)-based tests for SARS-CoV-2 infection (n=8062) or received hospital-based International Classification of Diseases version-10 (ICD-10) codes for COVID-19 (n=1943) between February 1, 2020 and December 31, 2020. Population controls (n=217 730) and propensity score-matched controls (n=38 860) were also drawn from the UK Biobank during the same period. Proportional hazard models were used to evaluate COVID-19 for association with long-term (>1000 days) risk of MACE and as a coronary artery disease risk equivalent. Additional analyses examined whether COVID-19 interacted with genetic determinants to affect the risk of MACE and its components.ResultsThe risk of MACE was elevated in COVID-19 cases at all levels of severity (HR, 2.09 [95% CI, 1.94-2.25]; P
- Published
- 2024